In contrast to cHL, NHL has shown variable and generally less robust responses to ICIs compared to cHL, likely due to differences in tumor-infiltrating immune cell composition and PD-L1 expression [13]. The gene discussed is CD274; the disease is non-Hodgkin lymphoma.